Grilling: FDA Commissioner Andrew von Eschenbach testified at a congressional hearing on the contaminated pharmaceutical drug heparin Tuesday.
Susan Walsh

Tainted Chinese imports spur calls to protect consumer

Toxic blood thinner may have killed as many as 81 people, US says.

Page 1 of 2

Reporter head shot

This feature requires a newer version of Macromedia Flash Player and javascript-enabled browser.

Get Flash Player

Reporter Peter Grier discusses current trade issues between the US and China.

Lead in toys. Melamine in pet food. Toxic chemicals in toothpaste. And now, tainted pharmaceuticals.

The unfolding scandal of contaminated blood thinner from China is the latest in a string of revelations about dangerous imports from a country that has risen to become manufacturer to the world.

US lawmakers now are pushing for more protection for American consumers, as hearings in Congress this week have made clear. Even the head of the Food and Drug Administration (FDA) says he needs more money – and a new approach – to try and ensure that products entering the country are safe.

Other countries may well follow suit. In a world of increasingly globalized commerce, the next frontier may not be more or cheaper goods, but higher quality trade, says Moisés Naím, editor in chief of Foreign Policy magazine.

"What is now happening [with contaminated products] is going to create a big surge in consumer protection demands and expectations," says Mr. Naím, author of "Illicit," a book that details some of the problems of globalization.

According to the FDA, as many as 81 Americans may have died after taking heparin, a blood thinning agent, tainted in China via the addition of a poisonous chemical. US recalls of Chinese heparin ingredients began in February.

Chinese officials don't agree that the deaths were caused by contamination that may have occurred in their country. They say that the problem could stem from manufacturing of the finished drug at a plant in New Jersey.

At a House hearing Tuesday, lawmakers chastised the FDA for not increasing its focus on foreign drug makers after the heparin crisis and other contamination scares.

The FDA inspects domestic drug plants every 2.7 years, on average, they noted. But at the rate they are moving, it would take 13 years to check every foreign drug plant and 1,900 years to check every foreign food plant that ships products to the US.

"It's clear the FDA needs some new thinking on how to deal with the 21st century," said Rep. Joe Barton (R) of Texas.

Page 1 | 2 | Next Page

Related Stories
Get Monitor stories by e-mail:
(Your e-mail address will be protected by csmonitor.com's tough privacy policy.)
(Mary Knox Merrill/Staff)
EDITOR'S PICK Five cities that will rise in the New Economy
From Seattle to Huntsville, Ala., five cities are poised to prosper in the New Economy because of exports, innovation, clean technology, and healthcare.

In Pictures:
Get ready for gridlock
POLITICS Patchwork Nation
The American voter beyond red and blue

Daily podcast

Monitor Reports

Discussions with Monitor reporters from around the world


Today

Peter Grier

The Monitor's Peter Grier talks with reporter Ron Scherer about how Black Friday will effect the economy this year.




Making a difference
Making a Difference

What happens when ordinary people decide to pay it forward? Extraordinary change. See how individuals are making a difference, finding solutions, overcoming adversity, and giving back globally.

Batdorj Gongor convinces residents to set up savings groups as a way of teaching them the power they gain by banding together in neighborhoods.

Lee Lawrence

People making a difference: Batdorj Gongor

In Mongolia, he shows former nomads how working together benefits everyone.